AFT Pharmaceuticals Limited

Overview

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

Performance

The following information was extracted from AFT Pharmaceuticals Limited's Market Update, released on 06 October 2026:

September quarter investor update

AFT reports double digit revenue growth in 1H FY27 and R&D progress

HIGHLIGHTS

• On track to reach $300 million FY27 revenue target with all divisions showing double digit revenue growth in 1H FY27
• FY27 operating profit guidance affirmed at $28 million to $32 million
• Maxigesic IV out licensed in Japan and the Philippines
• AFT’s fridge-free medicines R&D partner, StablePharma gains further validation for its technology
• Achieved our third US FDA approval for a patented product with tentative approval of ScomaraTM
• R&D pipeline progress including novel iron injectable product first study sites activated
• Successful launch of Maxigesic (Combogesic) Rapid in the US with Mark Cuban’s Cost Plus Drugs Company

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company1, today announces sustained double-digit revenue growth for 1H FY27. It also reports it remains on track to deliver its FY27 $300 million revenue target and operating profit guidance of $28 million to $32 million.

AFT Managing Director Dr Hartley Atkinson said: “We are pleased with our half year sales progress and the ongoing advances we have made to extend our global footprint with Maxigesic® IV out-licensing agreements in both Japan and the Philippines and good progress with our R&D development pipeline. We are looking to the remainder of the financial year with confidence.”